Role of Polymorphisms in the IL-1 Gene Cluster
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Glaucoma, an optic neuropathy characterized by progressive visual field loss, is the leading cause of irreversible blindness worldwide. The condition has a substantial heritable basis, as illustrated by the numerous loci and genes identified to date, and the large proportion of patients having a family history.
Interleukin-1 (Il-1) is an important mediator of inflammation. There are 2 pro-inflammatory cytokines, Il-1 alpha and Il-1 beta. The genes encoding Il-1 are located within a 430kb region on chromosome 2q14.2. The role of Il-1 in glaucoma is a subject of recent interest. It has been shown that Il-1, produced endogenously by glaucomatous cells, inhibits the apoptotic response to oxidative stress, and Il-1 has also been reported to increase outflow facility by stimulating the _expression of matrix metalloproteinase enzymes, which in turn reduces extra cellular resistance. Recently, polymorphisms in Il-1 (particularly +3953T of the Il-1 β) were found to reduce the risk of primary open angle glaucoma. In this pilot study, we aim to investigate the role of Il-1 polymorphisms in both normal tension and high pressure glaucoma in our glaucoma patients. Both open and closed angle glaucoma will be studied. This is a pilot study of the role of immune system related polymorphisms and depending on the results, we may embark on a larger investigation of other immune genes in glaucoma
| Condition |
|---|
|
Glaucoma |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Primary Purpose: Screening Time Perspective: Cross-Sectional Time Perspective: Prospective |
| Official Title: | Investigating the Genetic Basis of Glaucoma: Role of Polymorphisms in the IL-1 Gene Cluster |
| Estimated Enrollment: | 400 |
| Study Start Date: | July 2005 |
| Estimated Study Completion Date: | June 2006 |
Show Detailed Description Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Standardized inclusion criteria for glaucoma will be used, which is the presence of glaucomatous optic neuropathy (defined as loss of neuroretinal rim with a cup:disc ratio of 0.7 or greater) with compatible visual field loss. PACG will be defined as the presence of at least 180 degrees of angle in which the trabecular meshwork is not visible on gonioscopy with the presence of glaucomatous optic neuropathy. POAG patients will have open angles on gonioscopy; POAG patients with a mean IOP without treatment that is consistently less than 21 mm Hg on diurnal testing will be classified as NTG.
There will be another 100 control patients with no clinical evidence of glaucoma recruited from the general clinics.
Exclusion Criteria:
- Individuals with secondary angle closure and other ocular diseases will be excluded.
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00346541 History of Changes |
| Other Study ID Numbers: | R423/18/2005 |
| Study First Received: | June 29, 2006 |
| Last Updated: | June 29, 2006 |
| Health Authority: | Singapore: Ministry of Health |
Keywords provided by Singapore National Eye Centre:
|
glaucoma polymorphism, genetic |
Additional relevant MeSH terms:
|
Glaucoma Ocular Hypertension Eye Diseases |
ClinicalTrials.gov processed this record on June 17, 2013